PDS Biotechnology Corp (PDSB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.220.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PDSB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on advancing PDS0301, the tumor-targeted IL-12 immunocytokine, through clinical trials including a randomized Phase 2b program.
Stated as a priority in 2 of last 2 quarters. Management emphasized advancing PDS0301 through a randomized Phase 2b development program and completed enrollment in a metastatic colorectal cancer trial. Clinical data published show encouraging response rates and survival, supporting progress. The trajectory is delivering on clinical advancement focus.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We expect to advance PDS0301 through a randomized Phase 2b development program.”
“Completed enrollment in metastatic colorectal cancer trial for PDS01ADC (PDS0301).”
Discontinue internal investment in PDS0101 and seek strategic partnerships or external funding for its continued development.
Stated as a priority in 2 of last 2 quarters. Management announced ceasing internal investment in PDS0101 and pursuing strategic partnerships. Intellectual property protections were strengthened in 2026-Q1. The company is maintaining focus on preserving PDS0101's value through partnerships, showing consistent strategic direction.
“Company will pursue strategic partnerships for continued development of PDS0101.”
“Strengthened intellectual property estate for PDS0101 with new patents granted.”
Focus on financial discipline including cost control and aligning operating expenses with strategic priorities.
Stated as a priority in 3 of last 3 quarters. Management implemented a workforce reduction in 2026-Q3 to align expenses with strategic priorities. Operating expenses decreased from $7.6M in 2025-Q2 to $6.5M in 2026-Q2, but net loss remained around $9.4M to $9.8M. The trajectory shows active cost discipline with limited improvement in net loss.
“Reduction in force approved to align operating expenses with strategic priorities.”
“Operating expenses decreased from prior year due to lower clinical and manufacturing costs.”
“Operating expenses remained high but management focused on cost control.”
Resolve Nasdaq listing deficiency due to stock price below minimum bid price requirement.
Newly stated in 2026-Q2. The company received a Nasdaq deficiency letter due to the stock price being below $1.00 for 30 consecutive business days as of July 31, 2026. This is a regulatory priority with no prior quarters stating this issue.
“Received Nasdaq deficiency letter for closing bid price below $1.00 minimum.”
Publish clinical trial data demonstrating efficacy of PDS01ADC and use results to support further development and regulatory progress.
Over the trailing year it converted 0.85x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.